ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,101.24
-0.29%
Dow Jones
44,424.25
-0.32%
US Dollar vs MXN
20.2749
0.00%
Brent Oil
77.625
0.00%
Bitcoin
104,784.57
0.05%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Adaptive Biotechnologies Corporation (ADPT) Cotización

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation (ADPT)

Adaptogenics Health Corp
7.99
-0.14
(-1.72%)
Cerrado 26 Enero 3:00PM
Delayed by 15 minutes
7.99
0.00
(0.00%)
Fuera de horario: 3:25PM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Estadísticas y detalles clave

Último Precio
7.99
Postura de Compra
7.39
Postura de Venta
8.27
Volume Operado de la Acción
895,707
7.875 Rango del Día 8.26
2.28 Rango de 52 semanas 8.33
Capitalización de Mercado [m]
1.179B
Precio Anterior
8.13
Precio de Apertura
8.08
Hora
17
@
8
Última hora de negociación
Volumen financiero
US$ 7,235,091
Precio Promedio Ponderado
8.0775
Volumen promedio (3 m)
1,420,099
Acciones en circulación
147,579,486
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-5.23
Beneficio por acción (BPA)
-1.53
turnover
170.28M
Beneficio neto
-225.25M

Acerca de Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for... Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
www.adaptivebiotech.com
Sede
Olympia, Washington, USA
Fundado
-
Adaptive Biotechnologies Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ADPT. The last closing price for Adaptive Biotechnologies was US$8.13. Over the last year, Adaptive Biotechnologies shares have traded in a share price range of US$ 2.28 to US$ 8.33.

Adaptive Biotechnologies currently has 147,579,486 shares in issue. The market capitalisation of Adaptive Biotechnologies is US$1.20 billion. Adaptive Biotechnologies has a price to earnings ratio (PE ratio) of -5.23.

ADPT Últimas noticias

Más noticias

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive...

22 Enero 2025
GlobeNewswire Inc.

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

SEATTLE and FORT MYERS, Fla., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics...

14 Enero 2025
GlobeNewswire Inc.

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

SEATTLE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive...

07 Enero 2025
GlobeNewswire Inc.

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive...

02 Enero 2025
GlobeNewswire Inc.

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment...

07 Diciembre 2024
GlobeNewswire Inc.

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive...

03 Diciembre 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

19 Noviembre 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

13 Noviembre 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

08 Noviembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Noviembre 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.9513.49431818187.048.336.6520082767.63849337CS
41.523.11248073966.498.335.9115806546.98265435CS
123.0963.06122448984.98.334.2714200996.12046634CS
263.8592.99516908214.148.333.84512582875.37658547CS
523.5278.74720357944.478.332.2813985994.29208181CS
156-7.78-49.334178820515.7718.022.2813086856.72102303CS
260-20.03-71.484653818728.0271.252.28115021217.07591266CS

ADPT - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Adaptive Biotechnologies?
El precio actual de las acciones de Adaptive Biotechnologies es US$ 7.99
¿Cuántas acciones de Adaptive Biotechnologies están en circulación?
Adaptive Biotechnologies tiene 147,579,486 acciones en circulación
¿Cuál es la capitalización de mercado de Adaptive Biotechnologies?
La capitalización de mercado de Adaptive Biotechnologies es USD 1.2B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Adaptive Biotechnologies?
Adaptive Biotechnologies ha negociado en un rango de US$ 2.28 a US$ 8.33 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Adaptive Biotechnologies?
El ratio precio/beneficio de Adaptive Biotechnologies es -5.23
¿Cuál es el ratio de efectivo a ventas de Adaptive Biotechnologies?
El ratio de efectivo a ventas de Adaptive Biotechnologies es 6.92
¿Cuál es la moneda de reporte de Adaptive Biotechnologies?
Adaptive Biotechnologies presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Adaptive Biotechnologies?
El último ingresos anual de Adaptive Biotechnologies es USD 170.28M
¿Cuál es el último beneficio anual de Adaptive Biotechnologies?
El último beneficio anual de Adaptive Biotechnologies es USD -225.25M
¿Cuál es la dirección registrada de Adaptive Biotechnologies?
La dirección registrada de Adaptive Biotechnologies es 711 CAPITOL WAY S STE 204, UNITED STATES, OLYMPIA, WASHINGTON, 98501 1267
¿Cuál es la dirección del sitio web de Adaptive Biotechnologies?
La dirección del sitio web de Adaptive Biotechnologies es www.adaptivebiotech.com
¿En qué sector industrial opera Adaptive Biotechnologies?
Adaptive Biotechnologies opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
EVAXEvaxion Biotech AS
US$ 5.99
(64.56%)
55.41M
ELABPMGC Holdings Inc
US$ 3.0901
(56.07%)
76.48M
PCLAPicoCELA Inc
US$ 4.60
(49.35%)
3.75M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
GODNUGolden Star Acquisition Corporation
US$ 3.11
(-75.82%)
17.51k
GODNGolden Star Acquisition Corporation
US$ 2.93
(-65.67%)
902.76k
NXTTNext Technology Holding Inc
US$ 1.37
(-54.93%)
2.56M
SGLYSingularity Future Technology Ltd
US$ 1.625
(-38.45%)
917.77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90.11
(-38.07%)
8
ACONAclarion Inc
US$ 0.0557
(28.94%)
811.91M
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
RIMEAlgorhythm Holdings Inc
US$ 0.0357
(4.69%)
284.97M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
NVDANVIDIA Corporation
US$ 142.62
(-3.12%)
232.88M

Discusión

Ver feed completo
KILLAZILLA KILLAZILLA 12 minutos hace
Whining on here WON'T help get back you $....
INQD
4u2nv2 4u2nv2 14 minutos hace
Patricia F Robaczewski and Michael lived next door. Talked to me about IFUS. I like him.
IFUS
fuagf fuagf 16 minutos hace
You should get it. Just on to it. I'll go the underdog. Go Alex...!!!
awesomed007 awesomed007 26 minutos hace
What is your point??
RDAR
Angelmin Angelmin 31 minutos hace
Hope Bessent does more than Mnuchin, who is big-mouthed, sneaky, and did little for us. I despise Mnuchin because he let us down and caused us to lose four years.
FNMA
Seminole Red Seminole Red 33 minutos hace
Here’s Everything Trump Did His First Week Back
From the southern border to the federal bureaucracy, Trump swiftly delivered on a slew of campaign promises

https://www.dailywire.com/news/heres-everything-trump-did-his-first-week-back?utm_source=facebook&utm_medium=social&utm_ca
JakeFromSF JakeFromSF 50 minutos hace
I just noticed something. George follows all of his tickers, but SR*W and GVSI don't follow him back? The GVSI one just happened too. Within the last day I noticed. A weird clue? Maybe. What it does mean is that the boy was on his GVSI account recently. Let's see it soon, George!
GVSI
archilles archilles 56 minutos hace
".......with his connection to CRTD a supposed company that rescues distressed stocks and fights against things like naked shorting etc. The Three C's are really long gone...."

1) Who needs naked shorts when it is suspected that the deep stock selling were done by insiders' family me
CRTD
igotthemojo igotthemojo 1 hora hace
“But I did, you're just not in the Facebook group where I did it,”

Lmao…sure…that must be it…SMFH
KBLB
edbi46 edbi46 1 hora hace
No WORD SALADS, no SUBSTANTIAL/NONE SUBSTANTIAL ACCUSATIONS, ( for like 13 years, from Oct. 2011 and counting?? ), did/will do any desired effect !!!!! We know they are watching BASHING work here, before the checks are being cut!!!


---------------------------------------------
BMI LMT MCF
4u2nv2 4u2nv2 1 hora hace
I just changed my mind about being a consultant. John, Bridgett, and Jessica talked to me tonight.
IFUS
BDEZ BDEZ 1 hora hace
Sad, thanks for sharing...
Seminole Red Seminole Red 1 hora hace
Bill Gates’s Next Big AI Bet:

STARGATE VIDEO

Bill Gates’s PC revolution in the 1980s gave investors a chance to turn $1k into more than
$3.7 million in Microsoft over the decades. I believe he’s about to mint new millionaires with his new AI project.
DMC8 DMC8 2 horas hace
https://stocktwits.com/SanDiegoLiving/message/601493069
AMRN
HoldEm777 HoldEm777 2 horas hace
You missed the point. The FCC issue has not gone away and Mexedia has dealt off Mexedia Inc (Phonetime) without their aquisition of Phonetime from Tellza ever getting the approval it needed from the FCC.
So revenue numbers are cart before horse imo.
RDAR
BornAgain BornAgain 2 horas hace
I am glad they are promoting their product at these shows, I hope it will be a plus for the company and the shareholders. Bring new eyes on the products and stock, not just an expensive vacation for the company's staff.
BWMG
CashCowMoo CashCowMoo 2 horas hace
How would it be $2 if there is nothing going in?
SBUM
lovethatgreen lovethatgreen 2 horas hace
$ MONI
MONI
zakattack zakattack 2 horas hace
You make up wild fantasies that can't be proven then nothing happenes and you pretend like you don't say these crazy dreams you're the troll not me
GNCP
doinit doinit 2 horas hace
loaded more in teens,,wanted to load even more...ran out of funds,,,lol
PTHRF
Quikshft Quikshft 2 horas hace
I would just say that if things are not going well, not filing quarterly's lets them not talk about it. How much more time would you give them before concluding things are not right? Perhaps they should spend some of the proceeds from the preferred D shares sale for additional accountants.
CRTG
doinit doinit 2 horas hace
PTHRF,,,headed for dollar land
PTHRF
AlwaysRed AlwaysRed 2 horas hace
It is believed that this post was wrong just like all the rest of your posts. Fear porn works great doesn't it?

Where is that 50 dollar silver?
Where is that dollar collapse?
where is that banking holiday?

Why are you still listening to clowns?
Think1st Think1st 2 horas hace
Were trying to make some money back.
While Pointing out we are in deep hole.
Because we never got off the ground.
Big ideas ,didn't pan out, endless no stop filings only to restart co in new direction with now more debt,
Co wants to get back in business to help investors
INQD
sunspotter sunspotter 2 horas hace
“ Exhibiting a complete lack of integrity must also be bliss.”

Ask Leo and Mr. Bean.

They’re the ones who stole your money after all, although to be fair it’s your own fault as you ignored all the warnings that brighter posters like loanranger and others gave you.
IPIX

Su Consulta Reciente

NASDAQ
ADPT
Adaptive Biotechnologies
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados